Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung

NCT02984761 2026-02-19

VALOR

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT05467748 2026-01-27

EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer

Phase 1/2 Recruiting

66 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06671613 2025-11-10

Stage IV NSCLC

Phase NA Recruiting

66 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Fasting

NCT06064279 2024-09-19

HAITEN-ICI

Phase 1/2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05430009 2022-08-01

Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer

Phase 1 Recruiting

12 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01574222 2018-01-18

VTNSCLC

Phase 1 Terminated

1 enrolled

Thoracic

Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Thoracic Neoplasms

NCT00108186 2014-10-29

Celecoxib Treatment for Lung Cancer

Phase 1 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Clinical Trials

RIVAL

VALOR

EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer

Stage IV NSCLC

HAITEN-ICI

Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer

VTNSCLC

Celecoxib Treatment for Lung Cancer